Customize this page|
2
Votes
vote
EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patientsMerck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors. ... |
|
0
Votes
vote
Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs(PHILADELPHIA) There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson. ... |
